Deficiency of miR-155 in Leukemic B-Cells Results in Cell Cycle Arrest and Deregulation of MIR155HG/TP53INP1/CDKN1A/CCND1 network
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články
PubMed
39591901
DOI
10.1016/j.arcmed.2024.103124
PII: S0188-4409(24)00175-9
Knihovny.cz E-zdroje
- Klíčová slova
- B-cells, CRISPR/Cas9, Cell cycle, Leukemia, miR-155,
- MeSH
- chronická lymfatická leukemie * genetika patologie MeSH
- cyklin D1 genetika metabolismus MeSH
- inhibitor p21 cyklin-dependentní kinasy * genetika metabolismus MeSH
- kontrolní body buněčného cyklu * genetika MeSH
- lidé MeSH
- mikro RNA * genetika metabolismus MeSH
- nádorové buněčné linie MeSH
- proliferace buněk genetika MeSH
- proteiny teplotního šoku MeSH
- regulace genové exprese u leukemie MeSH
- transportní proteiny genetika metabolismus MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- CCND1 protein, human MeSH Prohlížeč
- CDKN1A protein, human MeSH Prohlížeč
- cyklin D1 MeSH
- inhibitor p21 cyklin-dependentní kinasy * MeSH
- mikro RNA * MeSH
- MIRN155 microRNA, human MeSH Prohlížeč
- proteiny teplotního šoku MeSH
- TP53INP1 protein, human MeSH Prohlížeč
- transportní proteiny MeSH
BACKGROUND: Cell cycle progression and leukemia development are tightly regulated processes in which even a small imbalance in the expression of cell cycle regulatory molecules and microRNAs (miRNAs) can lead to an increased risk of cancer/leukemia development. Here, we focus on the study of a ubiquitous, multifunctional, and oncogenic miRNA-hsa-miR-155-5p (miR-155, MIR155HG), which is overexpressed in malignancies including chronic lymphocytic leukemia (CLL). Nonetheless, the precise mechanism of how miR-155 regulates the cell cycle in leukemic cells remains the subject of extensive research. METHODS: We edited the CLL cell line MEC-1 by CRISPR/Cas9 to introduce a short deletion within the MIR155HG gene. To describe changes at the transcriptome and miRNome level in miR-155-deficient cells, we performed mRNA-seq/miRNA-seq and validated changes by qRT-PCR. Flow cytometry was used to measure cell cycle kinetics. A WST-1 assay, hemocytometer, and Annexin V/PI staining assessed cell viability and proliferation. RESULTS: The limited but phenotypically robust miR-155 modification impaired cell proliferation, cell cycle, and cell ploidy. This was accompanied by overexpression of the negative cell cycle regulator p21/CDKN1A and Cyclin D1 (CCND1). We confirmed the overexpression of canonical miR-155 targets such as PU.1, FOS, SHIP-1, TP53INP1 and revealed new potential targets (FCRL5, ISG15, and MX1). CONCLUSIONS: We demonstrate that miR-155 deficiency impairs cell proliferation, cell cycle, transcriptome, and miRNome via deregulation of the MIR155HG/TP53INP1/CDKN1A/CCND1 axis. Our CLL model is valuable for further studies to manipulate miRNA levels to revert highly aggressive leukemic cells to nearly benign or non-leukemic types.
Al Farabi Kazakh National University Faculty of Biology and Biotechnology Almaty Kazakhstan
Department of Biochemistry Faculty of Science Palacký University Olomouc Czech Republic
Department of Chemical Biology Faculty of Science Palacký University Olomouc Czech Republic
Citace poskytuje Crossref.org
